NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
SIM0505 is a novel ADC developed by Simcere Zaiming. It is directed to CDH6, a promising anti-tumor target, using a unique binding epitope with increased tumor binding compared to competing candidates. It also features Simcere Zaiming's proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity while offering high systemic clearance to enlarge the therapeutic window. Preclinical studies have demonstrated robust anti-tumor activity across multiple solid tumor models and a promising safety profile in toxicology models.
SIM0505 is currently in Phase 1 dose escalation studies in China. A global dose expansion study is expected following the dose escalation portion of the study to include multiple tumor types. An Investigational New Drug application has been cleared by the U.S. Food and Drug Administration.
The partnership also includes a license for NextCure to access Simcere Zaiming's proprietary linker and TOPOi payload for a preclinical-stage novel target ADC developed by NextCure. Simcere Zaiming will have Greater China rights to this additional novel target ADC.
'We believe SIM0505 has the potential to be an important new therapy for cancer patients. Partnering with Simcere Zaiming, a leader in antibody-drug conjugates, provides us with an opportunity to advance a class-leading ADC directed to CDH6. Their proprietary payload is a potent cytotoxin with a potentially improved safety and efficacy profile compared to other topoisomerase inhibitors,' said Michael Richman, NextCure's president and CEO. 'We look forward to initiating clinical development of SIM0505 in the United States.'
'We are very pleased to collaborate with NextCure on the global development of SIM0505,' said Renhong Tang, PhD, CEO of Simcere Zaiming. 'SIM0505 is a significantly differentiated CDH6 targeting ADC candidate independently developed by Simcere Zaiming. Our alliance reflects NextCure's recognition of our proprietary ADC platform, and together, we aim to accelerate drug development to benefit more cancer patients worldwide.'
Simcere Zaiming is eligible to receive payments throughout the potential development phases, including upfront payment, development, regulatory and sales milestones up to $745M, as well as tiered royalties up to double digits on net sales outside of the Greater China territory.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. http://www.nextcure.com
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, 'Simcere'). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.
NextCure's Cautionary Statement Regarding Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'continue,' 'could,' 'should,' 'due,' 'estimate,' 'expect,' 'intend,' 'hope,' 'may,' 'objective,' 'plan,' 'predict,' 'potential,' 'positioned,' 'seek,' 'target,' 'towards,' 'forward,' 'later,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and not having any products approved for commercial sale; NextCure's history of significant losses; NextCure's need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure's ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described under the heading 'Risk Factors' in NextCure's most recent Annual Report on Form 10-K and in NextCure's other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
NextCure Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
[email protected]
Simcere Zaiming Contacts
PR contacts: [email protected]
IR contacts: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WIRED
30 minutes ago
- WIRED
An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US
Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for access to an AI-driven but entirely unproven treatment that includes injecting a highly concentrated dose of chlorine dioxide, a toxic bleach solution, directly into cancerous tumors. One patient tells WIRED her tumor has grown faster since the procedure and that she suspects it may have caused her cancer to spread—a claim Liu disputes—while experts allege his marketing of the treatment has likely put him on the wrong side of US regulations. Nonetheless, while Liu currently only offers the treatment informally in China and at a German clinic, he is now working with a Texas-based former pharmaceutical executive to bring his treatment to America. They believe that the appointment of Robert F. Kennedy Jr. as health secretary will help 'open doors' to get the untested treatment—in which at least one clinic in California appears to have interest—approved in the US. Kennedy's Make America Healthy Again (MAHA) movement is embracing alternative medicines and the idea of giving patients the freedom to try unproven treatments. While the health secretary did not respond to a request for comment about Liu's treatment, he did mention chlorine dioxide when questioned about President Donald Trump's Operation Warp Speed during his Senate confirmation hearing in February, and the Food and Drug Administration recently removed a warning about substance from its website. The agency says the removal was part of a routine process of archiving old pages on its site, but it has had the effect of emboldening the bleacher community. 'Without the FDA's heavy-handed warnings, it's likely my therapy would have been accepted for trials years earlier, with institutional partnerships and investor support,' Liu tells WIRED. He says he wrote to Kennedy earlier this year urging him to conduct more research on chlorine dioxide. 'This quiet removal won't immediately change everything, but it opens a door. If mainstream media reports on this shift, I believe it will unlock a new wave of serious [chlorine dioxide] research.' For decades, pseudoscience grifters have peddled chlorine dioxide solutions—sold under a variety of names, such as Miracle Mineral Solution—and despite warnings and prosecutions, have continued to claim the toxic substance is a 'cure' for everything from HIV to Covid-19 to autism. There is no credible evidence to back up any of these claims, which critics have long labeled as nothing more than a grift. The treatments typically involve drinking liquid chlorine dioxide on a regular basis, using solutions with concentrations of chlorine dioxide of around 3,000 parts per million (ppm), which is diluted further in water. Liu's treatment, however, involves a much higher concentration of chlorine dioxide—injections of several milliliters of 20,000ppm—and, rather than drinking it, patients have it injected directly into their tumors. Liu claims he has injected himself with the solution over 50 times and suffered no side effects. 'This personal data point encouraged me to continue research,' he says.
Yahoo
an hour ago
- Yahoo
A.O. Smith lifts annual profit forecast, considers China partnership
(Reuters) -Water heater maker A.O. Smith will consider strategic partnerships and other alternatives for its China business, it said on Thursday after raising its annual profit forecast. "We believe the China market has substantial long-term prospects and are committed to realizing the potential upside inherent in the company's China business for our company," CEO Steve Shafer said. The Milwaukee, Wisconsin-based company is banking on higher market share in the second half of the year and cost savings from its restructuring actions. It now expects annual adjusted earnings per share to be in the range of $3.70 to $3.90, compared with its previous forecast of $3.60 to $3.90. Analysts on an average expected $3.78 per share for 2025, according to data compiled by LSEG. But second quarter revenue fell about 1% from a year ago to $1.01 billion. Sales from other parts of the world, including China and India, also fell nearly 2% to $240.1 million. Net income for the quarter ended June 30 was $152.2 million billion, or $1.07 per share, compared with $156.2 million, or $1.06 per share, a year earlier.
Yahoo
an hour ago
- Yahoo
Apple (AAPL) Isn't Going To Buy Perplexity, Says Jim Cramer
We recently published . Apple Inc. (NASDAQ:AAPL) is one of the stocks Jim Cramer recently discussed. Apple Inc. (NASDAQ:AAPL)'s shares have lost 12% year-to-date as investors remain concerned about the firm's iPhone sales, lack of an AI product, and the impact of trade tensions between the US and China on its smartphone supply chain. In his previous comments about Apple Inc. (NASDAQ:AAPL), Cramer has asserted that CEO Tim Cook has to spend in America to build factories and infrastructure to boost local production. He discussed whether Apple Inc. (NASDAQ:AAPL) would acquire Perplexity this time around: '[On Morgan Stanley reiterates $235 and saying Services might be better than it thinks] Ben Reitzes is out there saying look the 200 dollar subscription if he buys Perplexity. Now, I was listening to my great friend Jeff Sonnenfield talk about how how unreliable these are and his conclusion was, well, you know you gotta be careful. You gotta look at them all. My conclusion is, why do you think they're building so many data centers? Because they're not scraping enough. People are building data centers because they want to line the pockets of GE Vernonva? I mean come on. They need more data centers because they're not accurate enough. But they will get accurate. And the idea of Apple buying Perplexity and doing subscription, they're not going to do it. They're not going to do it because they don't buy anybody. But you know that is the hobgoblin of little [inaudible] there. You gotta buy, you need AI.' While we acknowledge the potential of AAPL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
